Altos Vision Ltd.

Ophthalmic

Clive H. Reading
Chief Executive Officer

5 Sylvan Way
Parsippany, NJ 07054
USA

www.altosvision.com

1 (973) 254-3595

Ownership: Private

Highlights

Recent	*Upcoming*
Establishment of Altos and a management team of 4 with over 50 years senior pharmaceutical ophthalmology experience. Licensing of iDESTRIN on favorable terms.	Start of Phase III trial and completion of trial. Start commercializing iDESTRIN within 3 years from receipt of funding.

Corporate Mission

To be a leading specialty pharma company focused on ocular diseases by developing and commercializing prescription eye products and creating an effective global marketing and sales organization while being a cash efficient company.

Proprietary Technology

iDESTRIN™ is a prescription drug for the treatment of dry eye in postmenopausal women. This product is ready to commence Phase III trial activities two months after receiving the Round A $7 million funding.

Corporate Alliances

None

Products

Name	*Phase*	*Indication*	*Milestone*
iDESTRIN	Phase III	Dry Eye Syndrome	Completion of PIII

Senior Management

Clive H. Reading, Chief Executive Officer • **Una Ryan**, Chairman • **Mario Fsadni**, Chief Medical Officer • **Tom Rowe**, Vice President • **Rick Coulon**, Vice President

Financing History

Round Date (Amount, US$): December 2008

Asiatic Clinical Research Private Ltd.

Service • Other

Bindhu Aravapalli
Director

300 Aurelia Trace
Alpharetta, GA 30004
USA

www.asiaticlinical.com

1 (678) 805-4440

Ownership: Private

Highlights

Recent	*Upcoming*
Completed recruitment of 200 patients in an OA study in a record 60 days.	Working on a tie up with a Europe CRO

Corporate Mission

Vision: To be a globally competitive, end-to-end clinical research facility.

Mission: We strive to adhere to the best international practices in clinical research while maintaining the highest ethical standards in our services.

Proprietary Technology

In house s/w product used for Electronic Data Capture

Corporate Alliances

Biocancer Brazil

Trial Pro USA

Senior Management

Bindhu Aravapalli, Director • **Mithra**, Director • **Prasad Tagat**, Director

Astrenia Therapeutics, Inc.

Musculoskelatal • Metabolic Disease • Drug Development

Jake Schaible
President & CEO

5340 Toscana Way, Suite 202
San Diego, CA 92122
USA

www.toscanavent.com

1 (858) 652-1392

Incorporated: 2008
Ownership: Private

Highlights

Recent	*Upcoming*
Incorporated and seed funded	Complete Spinout Transaction in 1H09
Completed negotations on terms for lead program	Complete Series A Financing
	Initate Phase II trials with lead NCE

Corporate Mission

Astrenia Therapeutics, Inc. is a private, emerging biopharmaceutical company focused on developing clinical stage novel therapies for musculoskeletal disorders and metabolic disease.

Proprietary Technology

The lead is a Phase II ready NCE, with utility in multiple acute & chronic indications of major unmet medical need. First in class potential, this oral, once daily pill looks to provide superior efficacy, safety & tolerability over the older products in the area. The lead has strong Ph I & NHP data, an open IND, and supplies for the whole Ph II program.

Senior Management

Jake Schaible, President & CEO

Bristol-Myers Squibb Company

James M. Cornelius
Chief Executive Officer

Rt. 206 & Province Line Road
Princeton, NJ 08540
USA

www.bms.com

1 (609) 252-4000

Incorporated:	1989
Employees:	43,000
Ownership:	Public
New York Stock Exchange: BMY	

Highlights

Recent

Bristol-Myers Squibb recently acquired Kosan Biosciences. The acquisition will enhance BMS' pipeline with compounds in two important classes of anticancer agents: novel Hsp90 (heat shock protein 90) inhibitors and epothilones.

Bristol-Myers Squibb & KAI Pharmaceuticals will develop KAI-9803, an inhibitor of the delta protein kinase C pathway which is designed to reduce the size of the heart attack & to improve clinical outcomes during treatment of acute myocardial infarction.

ABILIFY received expanded indications in Bipolar I Disorder & Schizophrenia - now indicated for maintenance treatment of manic & mixed episodes associated w-Bipolar I Disorder in pediatric patients & maintenance treatment of Schizophrenia in adolescents.

Corporate Mission

A Next-Generation BioPharma Leader

Around the world, Bristol-Myers Squibb medicines help millions of patients in their fight against serious diseases such as cancer, heart disease, diabetes, HIV/AIDS, rheumatoid arthritis, hepatitis B and psychiatric disorders.

By combining the resources of a major pharmaceutical company with the can-do spirit of an innovative biotech company, we are transforming into a new kind of enterprise – a next-generation BioPharma leader. Since 2002, we've introduced nine new medicines for the treatment of psychiatric disorders, cancer, HIV and other serious diseases. Two of the medications are biologic products.

To accelerate the discovery and development of important new therapies, we are complementing and enhancing our internal capabilities with innovative alliances, partnerships and acquisitions. We call this our "String of Pearls" strategy.

Senior Management

James M. Cornelius, Chief Executive Officer

Cell Line Genetics, LLC

Regenerative Medicine • Genetic Disorders • Service

Roberto Herrera
President

510 Charmany Drive
Madison, WI 53719
USA

www.clgenetics.com

1 (608) 441-8160

Incorporated:	2006
Employees:	8
Ownership:	Private

Highlights

Recent

Cell Line Genetics receives $250,000.00 loan from the State of Wisconsin for product development.

Senior Scientists Lorraine Meisner and Julie Johnson highlighted on December issue of Nature Methods.

Corporate Mission

Cell Line Genetics (CLG) provides quality assurance products and services to biotech and pharmaceutical companies, as well as universities and research institutes engaged in Stem Cell and Cancer Research.

CLG currently offers services including chromosome analysis, FISH (fluorescent in situ hybridization), DNA fingerprinting and culture cross-contamination detection. The company also provides custom research services.

With recurring cash flow from a high-profile customers base, CLG is poised to deliver proprietary stem cell quality control products and kits for the growing regenerative medicine market.

Proprietary Technology

The Critical Region Assay (CRAs) is a patent-pending technology solely owned by Cell Line Genetics. In addition, a number of techniques in the detection of anomalies in cell lines are also considered proprietary.

Corporate Alliances

Available upon request

Products

Name	*Phase*	*Indication*	*Milestone*
Stem Cell Characterization	On Market	Detection of abnormalities in Stem Cells - Service	
Cancer Cell Line Characterization	On Market	Detection of abnormalities in Cancer Cell Lines - Service	
Critical Region Assay	Research	Anomaly detection	TBD

Senior Management

Roberto Herrera, President • **Lorraine Meisner, PhD**, Chief Scientific Officer • **Julie Johnson, MS, CPSp**, Partner • **Roberto Herrera**, Chief Business Officer

Financing History

Investors: **Company Founders (Herrera, Meisner, Johnson)** (100 %)

Colby Pharmaceutical Company

Oncology • Urological • Neurology

David Zarling PhD, MBA
Chief Executive Officer

1095 Colby Ave, Suite C
Menlo Park, CA 94025
USA

www.colbypharma.com

1 (650) 333-3150

Incorporated:	2007
Employees:	3
Ownership:	Private

Highlights

Recent

Colby became a Licensee of 3 small molecule signal transduction inhibitor drugs from Wisconsin Alumni Research Foundation (WARF). These drugs are CPC-100, -200, and -300 which are therapeutic Rx's for different stages of recurrent prostate cancer.

Colby accesses two NCI grants covering costs for all of the CPC-100 and CPC-200 IND-enabling data packages.

Colby files its own patents for CPC-410 & other new chemical entity targeted drugs for metastatic prostate and other radiation-resistant and chemo-therapy resistant cancers as first-line Rxs or in conjunction with current standard of care Rxs.

Upcoming

A1. Colby files CPC-100 IND.

A2. Colby completes Series A to fund clinical drug development of lead drug, CPC-100.

B1. Colby completes GLP toxicology for CPC-200 which is completely funded by NCI.

C1. Colby collects IND-enabling data for CPC-410.

C2. Colby in-licenses CPC-010 Phase IIb.

Corporate Mission

Colby intends to clinically develop & sell prostate cancer (PCa) drugs for the different stages of recurrent PCa. These drugs are new oral small molecule drugs for PCa & other solid tumors. About 15% of primary PCa patients fail surgery or radiation, as diagnosed by rises in PSA. Most recurrent PCa patients receive androgen deprivation therapy (ADT), via chemical or surgical castration. ADT modestly prolongs survival, but side-effects include osteoporosis, decreased libido, weight gain, menopausal symptoms, fatigue, gynecomastia and breast tenderness, leaving 1/3 of these patients reluctant to continue ADT for asymptomatic PCa, with rising serum PSA levels, post-surgery. Most PCa becomes unresponsive to ADT. There is little effective treatment for asymptomatic ADT-refractory PCa patients. Docetaxel chemo, given to men with symptomatic metastatic PCa, demonstrates only modest survival benefits. Colby's drugs stop PCa progression and significantly increase survival in animal models, with no side-effects, even after prolonged treatment. Colby's drugs are safe/efficacious in animals. The company in-licensed CPC-100, -200, -300 from WARF and is strategically aligned. Colby's drugs have unique MOAs & inhibit multiple signal transduction (CPC-100 & -300) paths or inhibit a distinct single-target signal transduction path (CPC-200 & -410). CPC-410 was developed in-house and is a mitochondria-targeted inhibitor drug for therapy-resistant prostate & brain tumors. Colby drugs fill unmet needs, where there are no existing drugs available or where current standard of care drugs are ineffective and have intolerable side effects. The resistance of recurrent PCa to all therapeutics calls for novel drugs and Colby's mission is to develop and commercialize effective and safe novel therapeutic drugs for treatment of unmet medical needs of patients with recurrent prostate & brain cancer.

Proprietary Technology

Colby and collaborators are developing molecularly targeted signal transduction inhibitor drugs which are therapeutic for prostate cancer and certain other solid tumors (i.e. GBM).

Corporate Alliances

The company has exclusively in-licensed 3 small molecule drugs, CPC-100, -200, -300 from the Wisconsin Alumni Research Foundation (WARF) and is strategically aligned with WARF, UW-Madison and the UW Clinical Cancer Center (UWCCC).

Products

Name	*Phase*	*Indication*	*Milestone*
CPC-100	Phase I	post-ADT prostate cancer who failed ADT and now with rising PSA	IND-enabling data completed
CPC-200	Optimized Lead	pre-ADT prostate cancer in men with rising PSA, no exidence of metastasis	IND-enabling data to be complete by 3Q2009
CPC-410	Optimized Lead	radiation and chemotherapy resistant Glioblastoma multiformae brain cancer	IND-enabling data to be completed by1H2010

Senior Management

David Zarling PhD, MBA, Chief Executive Officer • **Hirak Basu, PhD**, Chief Scientific Officer • **Minesh Mehta, MD**, Chief Medical Officer • **Anne Vallerga, MA, PhD**, Vice President • **Bill Massey, PhD**, Chief Operating Officer

Financing History

Round Date (Amount, US$): February 2008 (0.70 Million)

Investors: **Wisconsin Alumni Research Foundation** (22 %) • **Private Investors & Co-Founders** (71 %)

Cubist Pharmaceuticals, Inc.

Infectious Disease • Cardiovascular Disease

Michael W. Bonney
President & CEO

65 Hayden Avenue
Lexington, MA 02421
USA

www.cubist.com

1 (781) 860-8660

Incorporated:	1992
Employees:	550
Ownership:	Public
NASDAQ: CBST	

Highlights

Recent

FDA approval for the sNDA for CUBICIN® (daptomycin for injection) as once-a-day therapy at 6 mg/kg for the treatment of S. aureus bloodstream infections (bacteremia, including right-sided endocarditis, caused by MSSA and MRSA.

CUBICIN®, our first in class IV antibiotic, has experienced the most successful IV antibiotic launch, in dollar terms, in U.S. history. Our historical sales trends since launch demonstrate the significant growth potential for CUBICIN®.

CUBICIN® launch in Europe beginning March 2006.

Upcoming

Advance Lipopeptide, CDAD, and Natural Products Discovery Research.

Continued double digit revenue growth for CUBICIN®.

Complete IND enabling studies for IB657.

Corporate Mission

Cubist Pharmaceuticals, Inc., is a biopharmaceutical company focused on the research, development and commercialization of products that address unmet medical needs in the acute care product environment. To date, Cubist has been exclusively focused on developing business and product opportunities in the antiinfective marketplace. The company's flagship drug, CUBICIN® (daptomycin for injection) is a first in class lipopeptide proven clinically successful against both methicillin susceptible and methicillin resistant Staphylococcus aureus (MSSA and MRSA) infections for skin and skin structure/soft tissue (cSSSI/cSSTI) and bacteremia (SAB), including right-sided infective endocarditis (RIE)*. Other defining characteristics for the drug include: Unique mechanism of action; Once-daily dosing, 30 min. infusion, limited drug monitoring; and Rapidly bactericidal in vitro against MRSA/MSSA.

In addition to expanding the indications and international markets for CUBICIN®, Cubist plans to grow through product pipeline additions developed internally or sourced externally. Cubist's Lipopeptide Program is focused on the discovery and development of bactericidal lipopeptide drug candidates which have the antimicrobial spectrum and safety profile of daptomycin, and also have efficacy in lung infections. Cubist is headquartered in Lexington, MA.

* Complete FDA approved label available at www.cubist.com .

Proprietary Technology

Cubist owns multiple proprietary assets and technologies in the area of natural products that are being applied to discover novel antiinfective agents that attempt to eliminate the bottlenecks that currently exist in the natural products drug discovery process.

Corporate Alliances

Cubist Pharmaceuticals, Inc. and Novartis (through its Subsidiary Chiron Corporation) entered into a license agreement for the development and commercialization of Cubist's antibiotic CUBICIN in Western and Eastern Europe, Australia, New Zealand, India and certain Central American, South American and Middle Eastern countries.

Products

Name	*Phase*	*Indication*
CUBICIN (daptomycin)	Cleared for US Marketing	CSSSi, SAB, Endocarditis
Merrem (merropenem)	Cleared for US Marketing	SSSI, IBI, bacterial meningitis
Ecallantide	Phase II, IIa, IIb	Prevention of bleeding in CTS
ALN-RSV01	Phase II, IIa, IIb	RSV
CB-183.315	IND Filed	CDAD
CB-182.804	IND Filed	Gram-negative infections

Senior Management

Michael W. Bonney, President & CEO • **Robert J. Perez, MBA**, Chief Operating Officer • **Lindon M. Fellows**, Chief Technology Officer • **Steven Gilman, PhD**, Chief Scientific Officer • **Tamara L. Joseph, JD**, Vice President • **David W.J. McGirr, MBA**, Chief Financial Officer • **Santosh Vetticaden, MD, PhD**, Chief Medical Officer • **Gregory Stea**, Vice President

Scientific Advisory Board

Gordon Archer, MD, Chairman, Virginia Commonwealth University • **Bonnie Bassler, PhD,** Director, National Academy of Sciences, American Academy of Arts and Sciences • **Professor Eric Jacobsen,** Director, Sheldon Emery Professor of Chemistry, Harvard University • **Richard White, BSc, PhD,** Director, Consultant

Cypress Bioscience, Inc.

CNS • Diagnostics • AutoImmune

Jay Kranzler, MD, PhD
Chief Executive Officer

4350 Executive Drive
Suite 325
San Diego, CA 92121
USA

www.cypressbio.com

1 (858) 452-2323

Incorporated:	1981
Employees:	145
Ownership:	Public
NASDAQ: CYPB	

Highlights

Recent

Savella (milnacipran HCl) approved January 2009 for management of fibromyalgia. On market by mid-2009.

Personalized medicine services for rheumatoid arthritis launched October 2008.

February of 2009 acquired CB_CAP technology platform to diagnose and monitor autoimmune disorders, including systemic lupus erythematosus (SLE/Lupus).

Upcoming

Savella (milnacipran HCl) on market by mid-2009.

Lupus diagnostic application to launch mid-late 2010.

Corporate Mission

Cypress Bioscience, Inc. provides therapeutics and personalized medicine services to facilitate improved and individualized patient care. Cypress' goal is to address the evolving needs of specialist physicians and their patients by identifying unmet medical needs in the areas of pain, rheumatology, and physical medicine and rehabilitation, including challenging disorders such as fibromyalgia and rheumatoid arthritis. This approach to improving patient care creates a unique partnership with physicians. Current products include Savella™ (milnacipran HCl) and the Avise PGSM and Avise MCVSM therapeutic monitoring, diagnostic and prognostic tests for rheumatoid arthritis.

Our first pharmaceutical product, Savella (milnacipran HCl), was approved by the U.S. Food and Drug Administration (FDA) in January 2009 for the management of fibromyalgia, a chronic, debilitating disorder affecting up to 6 million Americans. Cypress Bioscience and our partner, Forest Laboratories, jointly market Savella in the US.

Avise PG is a proprietary test measuring methotrexate (MTX) polyglutamates, the active metabolites of methotrexate. MTX is a widely used first line treatment for rheumatoid arthritis (RA), prescribed alone and in combination with other non-biologic and biologic therapies. Avise MCV is a sensitive and specific personalized medicine test that improves upon traditional means of diagnosing RA. Early diagnosis and appropriate treatment of RA are critically important in the prevention of erosive joint destruction and disability. Avise MCV measures antibodies to mutated citrullinated vimentin, a protein found in the inflamed synovium of patients with RA. Elevated levels of anti MCV not only indicate an increased likelihood of having rheumatoid arthritis, but have also been shown to identify those who may develop more severe forms of RA.

Proprietary Technology

Avise PG is a proprietary test measuring methotrexate (MTX) polyglutamates, the active metabolites of methotrexate. Avise MCV is a sensitive and specific personalized medicine test that improves upon traditional means of diagnosing RA.

Corporate Alliances

In January 2004, Cypress entered into an agreement with Forest Laboratories for the development and marketing of Savella (milnacipran HCl), licensed from the product's originator, Pierre Fabre Médicament, for indications in the U.S. market.

Products

Name	*Phase*	*Indication*	*Milestone*
Savella (milnacipran HCl)	On Market	Fibromyalgia	FDA approved January 2009
Avise PG	On Market	Rheumatoid Arthritis	Launched October 2008
Avise MCV	On Market	Rheumatoid Arthritis	Launched October 2008
CP-CAP technology platform	Other	SLE/Lupus	Launch 2010

Senior Management

Jay Kranzler, MD, PhD, Chief Executive Officer • **Sabrina Johnson**, Chief Financial Officer • **Michael Gendreau, MD**, Chief Medical Officer • **Srinivas Rao, MD, PhD**, Chief Scientific Officer • **Michael Walsh**, Other

Embera NeuroTherapeutics, Inc.

Neurology • CNS • Drug Development

Bob Linke
Chief Executive Officer

BioSpace1, 2031 Kings Highway
Shreveport, LA 71103-3642
USA

www.emberaneuro.com

1 (617) 719-9406

Incorporated: 2005
Ownership: Private

Highlights

Recent

Embera is a venture backed specialty pharmaceutical company founded by Louisiana Ventures and the Louisiana Fund.

Corporate Mission

Embera NeuroTherapeutics, Inc. is a development stage, specialty pharmaceutical company formed to develop and commercialize novel treatments for a broad range of addictions. The company has begun clinical testing and plans to commercialize a patent-pending drug combination (EMB-001) which is expected to target specific brain functions that are associated with craving and relapse.

The novel, proprietary Embera approach works by blunting craving centers in the brain, offering a new way to address substance abuse, a significant, growing problem in the United States and worldwide. The company intends to capitalize on the lack of existing medications for treatment of addiction, by developing a medical therapy which can be used along with appropriate supportive psychological care, to induce abstinence and to prevent or reduce relapse of substance abusers. This approach would be integrated into comprehensive substance abuse treatment programs.

Proprietary Technology

Embera's EMB-001 works by targeting two components of addiction control, essentially "taking the foot off the accelerator while applying the brake", in order to calm brain circuits. EMB-001 prevents over-activation of the stress response system (takes the foot off the accelerator), while simultaneously providing an inhibitory (braking) effect on the circuits that are prone to hyperexcitability.

Products

Name	*Phase*	*Indication*
EMB-001	Other	Cocaine Dependence
EMB-001	Preclinical	Obesity
EMB-001	Preclinical	Smoking Cessation
EMB-001	Preclinical	Alcohol Dependence

Senior Management

Bob Linke, Chief Executive Officer • **Nicholas Goeders, PhD**, Chief Scientific Officer

Gemin X Pharmaceuticals

Oncology

Glenn J. Gormley, MD, PhD
President & CEO

400 Chesterfield Parkway
Malvern, PA 19355
USA

www.geminx.com

1 (610) 640-5735

Incorporated:	1998
Employees:	50
Ownership:	Private

Corporate Mission

Gemin X Pharmaceuticals is developing first-in-class small molecule cancer therapeutics based on reinitiating programmed cell death (apoptosis), inducing cancer cell self-digestion (autophagy), and the inhibition of metabolism in cancerous cells. Gemin X currently has several development programs underway, spanning a broad range of hematological and solid tumor cancers. It's most advanced product candidate is obatoclax (GMX15-070), currently in a Phase 2 combination study in small cell lung cancer, and preparing to enter additional Phase 2 studies in mastocytosis and acute lymphoblastic leukemia (ALL). Gemin X's second product in development is GMX1777, an inhibitor of NAD+ metabolism, which is expected to enter into Phase 1b clinical studies in chronic lymphocytic leukemia (CLL) and melanoma in 2009. In addition, Gemin X has a number of cancer drug development programs in preclinical development.

Proprietary Technology

The company's clinical candidates include obatoclax (GX15-070) and GMX1777; in addition, Gemin X has novel targeted agents in preclinical development.

Corporate Alliances

The company intends to advance its portfolio of drug candidates internally through preclinical and early stage clinical development, and subsequently may seek a co-development alliance with an experienced Oncology Drug Development company.

Products

Name	*Phase*	*Indication*
Obatoclax	Phase II, IIa, IIb	SCLC, ALL, Mastocytosis
GMX1777	Phase I	CLL, Melanoma

Senior Management

Glenn J. Gormley, MD, PhD, President & CEO • **Jean Viallet, MD**, Chief Medical Officer • **Gordon Shore, PhD**, Chief Scientific Officer • **Michael Dixon, CA**, Chief Financial Officer • **Art Fratamico, R.Ph**, Vice President • **Jeff Hincks, PhD**, Vice President • **Mark Berger, MD - Clinical Dev.**, Vice President • **Edwina Wyatt-Knowles, BSc Clinical Ops**, Vice President • **Pierre Beauparlant, PhD - Research**, Vice President

Genentech, Inc.

Oncology • AutoImmune • Neurology

Arthur D. Levinson, PhD
Chief Executive Officer

1 DNA Way
South San Francisco, CA 94080-4990
USA

www.gene.com

1 (650) 225-1000

Incorporated:	1987
Employees:	11,000
Ownership:	Public
New York Stock Exchange: DNA	

Corporate Mission

Our mission is to be the leading biotechnology company, using human genetic information to discover, develop, commercialize and manufacture biotherapeutics that address significant unmet medical needs. We commit ourselves to high standards of integrity in contributing to the best interests of patients, the medical profession, our employees and our communities.

Corporate Alliances

Our Alliance Strategy

Developing alliances has been one of Genentech's key strategies for success from its inception. Several marketed products and products in clinical development have arisen from successful collaborations. Genentech considers collaborations wherever there is excellent science and the potential for a good strategic fit. Genentech is dedicated to bringing considerable resources to the alliance, and is open to different collaboration structures. Genentech has the resources of a large company, including world-class research, clinical, and sales and marketing expertise, but has retained the energy and drive of a small, growing company.

Senior Management

Arthur D. Levinson, PhD, Chief Executive Officer • **Stephen G. Juelsgaard, DVM, JD**, Other • **Richard H. Scheller, PhD**, Chief Scientific Officer • **David A. Ebersman**, Chief Financial Officer • **Susan Desmond-Hellmann, MD, MPH, Product Dev.**, President • **Ian T. Clark**, Vice President • **Patrick Y. Yang, PhD**, Vice President

Johnson & Johnson

William C. Weldon
Chief Executive Officer

One Johnson & Johnson Plaza
New Brunswick, NJ 08933
USA

www.jnj.com

1 (732) 524-0400

Incorporated:	1886
Employees:	119,000
Ownership:	Public
New York Stock Exchange: JNJ	

Corporate Mission

As the world's most comprehensive and broadly based health care company, Johnson & Johnson with 2008 worldwide sales of $63.7 billion, is privileged to play a role in helping millions of people be well...and stay well. Johnson & Johnson is present in three (3) core areas of business: Pharmaceuticals, Medical Devices and Diagnostics, and Consumer Products. Caring for the world....one person at a time inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Johnson & Johnson is a unique company. And in the world in which change is the only constant, Johnson & Johnson is an enduring company. Our uniqueness goes well beyond the exceptional long-term financial results we have delivered for many decades. It derives from management philosophies that define our unique business model and have guided us through extraordinary changes in the science and economics of human health over much of the past century. We are: - Founded on shared values embodied in Our Credo. - Broadly based in human health care. - Decentralized in the way we operate the business. - Managed for the long term. While Johnson & Johnson continues to expand its portfolio, its pharmaceutical companies currently conduct research and/or market products in the following therapeutic categories: Anti-infectives; Cardiovascular Diseases; CNS; Gastroenterology; IMID (Immune Mediated Inflammatory Disease); Metabolic Diseases; Oncology/Hematology; Pain and Inflammation; Women's Health; Urology; Virology & Infectious Disease. Johnson & Johnson is also interested in biopharmaceutical products such as monoclonal antibodies, proteins and DNA vaccines.

Proprietary Technology

Johnson & Johnson has more than 230 operating companies, including: Johnson & Johnson Pharmaceutical Research and Development, L.L.C. (J&JPRD), Centocor, Inc. (a premier company in the development, production and commercialization of monoclonal antibodies), Janssen-Cilag, Ortho Biotech Products, L.P., Ortho McNeil, Inc. and its PriCara Unit, Ortho-McNeil Neurologics, Inc., Tibotec, Inc., Tibotec

Corporate Alliances

Johnson & Johnson is interested in a wide variety of pharma collaborations ranging from late-stage marketing collaborations to earlier-stage product and technology deals. The Johnson & Johnson Pharmaceutical Companies are searching for promising new compounds as well as new innovative technologies.

Senior Management

William C. Weldon, Chief Executive Officer

Jubilant Innovation (USA) , Inc.

Drug Development • Drug Discovery • Chemistry

Sridhar Mosur
Chief Executive Officer

1740 South Morgantown Road
Greenwood, IN 46143-8348
USA

www.jubilantbiosys.com

1 (317) 534-2540

Incorporated:	2007
Employees:	5,000
Ownership:	Private

Corporate Mission

Jubilant Innovation (JI) is the integrated drug development arm of the Jubilant group, a multibillion dollar Indian set of service companies that covers almost all aspects of small molecule drug discovery and development. JI contains a virtual drug development team, a business development group and a small venture fund. The JI business model is to offer the "India Advantage" of drug development to biotech partners, provide Jubilant infrastructure and capability at close to cost pricing, invest in worthy molecules of partners at up to 50% of the preclinical to phase II Proof Of Concept (POC) development funding requirement, and take its return at the end of POC with a percentage interest in the deal value of the asset at that time. With this model, JI is aligned with partners and investors by delivering low cost services and making a return based on the molecules that complete development successfully (as compared to other failed models that rewarded the CRO with its typical or even a greater margin for services regardless of success).

The Jubilant Group is listed on the Indian stock exchange under the parent company, Jubilant Organosys Ltd. (ticker: JOL), and comprises Jubilant Organosys, a provider of small molecule drug substance, drug product (oral, sustained release and injectable), and N-1 and N-2 intermediates; Jubilant Biosys Ltd., a provider of contract and shared risk small molecule discovery programs from target to candidate ready for major pharmaceutical and biotech companies; Jubilant Clinsys Clinical Research, a CRO providing regulatory and clinical services from phase I through phase IV across the USA, Europe and India. Jubilant has over 5000 employees in India and over 1500 in North America.

Proprietary Technology

Unlike a typical biotech, JI's business model is not based on a key technology. However, Jubilant capabilities include all aspects of small molecule drug discovery and drug substance and drug product, and drug development capability in oncology, neuroscience, pain and inflammation, metabolic and CV, and anti-infective diseases.

Corporate Alliances

- Integrated alliances with major pharma companies - Lilly, Amgen and Forest
- Alliances with biotech companies - Cellular Genomics, Entelos, and others
- Drug discovery and development - several USA based major universities
- Additional alliances across all three types of partners are close to announcement for first half 2009.

Products

Name	*Phase*	*Indication*
Kinase Discovery program	Phase I	Solid Tumors
GPCR Discovery Program	Preclinical	Multiple
Phosphodiesterase Discovery Program	Preclinical	Multiple
Nuclear Receptor Discovery Program	Preclinical	Multiple
Protease Inhibition Discovery Program	Preclinical	Multiple
Biomarker Discovery Program	Preclinical	Oncology, Metabolism

Senior Management

Sridhar Mosur, Chief Executive Officer • **V. N. Balaji, PhD**, Chief Scientific Officer • **Raman Govindarajan**, Vice President • **Jonathan P. Northrup (COO)**, Other

Karyopharm Therapeutics, Inc.

Michael Kauffman
President

83 Walnut Street
Wellesley Hills, MA 02481
USA

www.karyopharm.com

1 (781) 237-6050

Incorporated: 2008
Ownership: Private

Corporate Mission

Karyopharm Therapeutics is discovering and developing novel drugs designed to control the nuclear transport of proteins via the Nuclear Pore Complex (NPC). The NPC, which regulates both the import from and export to of proteins from the cytoplasm to the nucleus, is involved in transcriptional and cell cycle regulation. Abnormalities in the transport of key proteins have been demonstrated in a number of disorders. The Karyopharm team believes the NPC represents a novel and relatively unexplored target for drug discovery.

Senior Management

Michael Kauffman, President

Board of Directors

NS Pharma, Inc.

Urological • Hematology

Yoshihiko Makita
President

140 East Ridgewood Ave. 2nd FL
Paramus, NJ 07652
USA

www.nippon-shinyaku.co.jp

1 (201) 986-3860

Incorporated:	1991
Employees:	3
Ownership:	Private

Highlights

Recent

Nippon Shinyaku Co., Ltd. and Actelion Ltd. entered a license agreement on a novel orally available PGI2 receptor agonist NS-304 originally discovered and synthesized by Nippon Shinyaku Co., Ltd. for the treatment of PAH.

Nippon Shinyaku Co., Ltd. initiated the marketing Lunabel which was developed by Nobelpharma for the treatment of dysmenorrhea in gynecology.

Nippon Shinyaku Co., Ltd. is conducting Phase 1/2 studies of Azacitidine(Vidaza) for the treatment of MDS in Japan.

Corporate Mission

NS Pharma is a wholly owned subsidiary of Nippon Shinyaku Co., Ltd., which is headquartered in Japan. Nippon Shinyaku Co., Ltd. has been dedicated to developing and marketing ethical drugs in the fields of urology, gynecology, hematological malignancies, allergy and inflammation. Our main mission is to assist in-licensing of the candidates in the above fields to Nippon Shinyaku Co., Ltd.

Senior Management

Yoshihiko Makita, President • **Hironori Osaki**, Director

Financing History

Investors: **Nippon Shinyaku Co., Ltd.** (100 %)

PlexPress, Inc.

Systems Biology • Diagnostics • Gene/Cell Therapy

Robert Dunkle
Chief Executive Officer

3945 Freedom Circle
Santa Clara, CA 95054
USA

www.plexpressbio.com

1 (650) 678-2341

Incorporated:	2007
Employees:	12
Ownership:	Private

Highlights

Recent

Now that the human genome has been determined, understanding gene function is paramount. PlexPress has invented a novel HT method to analyze the expression of multiple genes by measuring RNA directly from cell lysate and eliminating PCR amplification.

This economical, accurate method opens new vistas for experimentation and to explore system biology. Significantly, these measures can be generated from genes known to be important in a disease or treatment and from gene arrays custom to the experiment.

Exploring the impact of differences in candidate drug compounds, protocols, and environmental conditions on gene expression can be analyzed. Thus, one can understand determinates of gene expression AND that impact on drug efficacy or toxicity.

Upcoming

Using PlexPress, researchers can analyze the characteristics of disease states and pathways over time providing important information for evidence-based decision making.

Target validation, lead optimization, preclinical assessments and clinical trials investigations will increasingly employ assessments of gene expression as a function of the biological system state over time to understand and validate outcomes.

New apps: POC diagnostics will employ multi-sample testing for patients providing broader coverage of disease states or wellness indicators. Biotech process development and control will increasingly rely on gene expression in production organisms.

Corporate Mission

To discover and provide methods and tools that enable researchers to gain insights to disease mechanisms, invent safe and effective drugs and establish methods to promote well-being. To enable insightful point of care diagnosis, information for appropriate therapeutic intervention and a means to monitor the effectiveness of treatment. To support new applications in chemical testing, food production, nutrition and bio processing.

Proprietary Technology

The PlexPress technology enables rapid and multiplex transcript analysis from large number of samples. The target mRNAs are hybridized with a pool of gene-specific detection probes and biotinylated oligo-dT capture probe. The RNA-probe complexes are captured on magnetic particles, washed, eluted and detected by capillary electrophoresis (CE). The technology features: - Multiplex detection.

Products

Name	*Phase*	*Indication*	*Milestone*
TRAC (TRanscriptional Analysis with aid of affinity Capture)	Cleared for US Marketing	All	Compliment VTT experience with additional applications.
Standard array family	Cleared for US Marketing	Multiple – by disease, by pathway, by biological system measures	Validation to standards and performance measures.
Custom array family	Cleared for US Marketing	Multiple – by disease, by pathway, by biological system measures	Validation to standards and performance measures.

Senior Management

Robert Dunkle, Chief Executive Officer • **Juhani Lahdenperä, MSc**, President & CEO • **Jari Rautio, DSc**, Chief Technology Officer • **Hans Söderlund**, Chief Scientific Officer

Spaltudaq Corporation

Infectious Disease • AutoImmune

David Fanning
Chief Executive Officer

1124 Columbia Street
Seattle, WA 98104
USA

www.spaltudaq.com

1 (206) 805-1600

Incorporated:	2005
Employees:	22
Ownership:	Private

Highlights

Recent

Early March 2009, Spaltudaq announced the discovery of two new antibodies, PG16 and PG9, that are more potent in neutralizing HIV infection in vitro than any human derived antibodies described to date.

Corporate Mission

Spaltudaq is a Seattle-based, discovery-stage biotech focused on the development of novel therapeutic antibodies for the treatment of infectious disease and inflammation. Our technology harnesses the power of the human immune system to identify naturally evolved monoclonal antibodies from the blood cells of immunologically relevant human subjects. Recombinant human monoclonal antibodies identified using our discovery platform may be uniquely relevant in combating disease and have potential as safe and effective therapeutic agents that could be administered to a broad patient population.

Proprietary Technology

I-STAR In Situ Therapeutic Antibody Rescue.

Corporate Alliances

International AIDS Vaccine Inititive.

Products

Name	*Phase*	*Indication*
Influenza	Preclinical	Influenza
HIV	Research	HIV
CMV	Research	CMV

Senior Management

David Fanning, Chief Executive Officer • **Matthew Moyle, PhD**, Chief Scientific Officer • **Russ Hawkinson**, Chief Financial Officer

Financing History

Investors: **Arch Venture Partners** • **Canaan Partners** • **Healthcare Ventures** • **Amgen Ventures** • **MPM Capital**

Thrasos Therapeutics, Inc.

Renal • Regenerative Medicine • Specialty Pharmaceutical

Richard Andrews
President & CEO

116 South Street
Hopkinton, MA 01748
USA

www.thrasos.com

1 (508) 589-4600

Incorporated:	2002
Employees:	4
Ownership:	Private

Highlights

Recent	*Upcoming*
Patent issued covering composition of matter on core compounds.	Completion of Phase 1 and 2a data in Acute Kidney injury clinical program.
Presentations of animal model data at ASN (November 2008) covering efficacy of compounds in multiple model of ischemic AKI and in Chronic renal disease.	Demonstration of efficacy of AA209 in chronic renal failure models.
	Selection of lead compound for application to reversal of EMT process in prostate cancer.

Corporate Mission

Thrasos Therapeutics, Inc. is a private, clinical stage, bio-therapeutics Company focused on the discovery and development of targeted therapies for the prevention and treatment of major organ failure. The company has created a rich portfolio of compounds (peptides) that are uniquely capable of selectively activating critically important receptors from the BMP family of proteins. The company's drug candidates have significant clinical potential for treating injury and disease affecting multiple organ systems and the company has demonstrated excellent results in the prevention and treatment of Acute Kidney Injury (AKI) and Chronic Kidney Disease (CKD) ---the company's primary clinical targets.

Proprietary Technology

The company's compounds were designed based on the structure of the Bone Morphogenetic Proteins (BMP). The company employs a technology called Structural Variant Analysis (SVA) to design compounds that target the BMP signaling pathway. The ability to activate this pathway selectively and controllably has led to a significant set of drug candidates with substantial commercial opportunity.

Products

Name	*Phase*	*Indication*	*Milestone*
AA 184	Optimized Lead	Acute Kidney Injury	Phase I
AA 209	Optimized Lead	Diabetic Nephropathy	
AA123	Preclinical	Cartilage repair and regeneration	

Senior Management

Richard Andrews, President & CEO • **Philippe Bey, PhD**, Other • **William D. Carlson, MD, PhD**, Chief Scientific Officer • **Peter Keck, PhD**, Other

Topica Pharmaceuticals, Inc.

Skin/Dermatological • Specialty Pharmaceutical • Infectious Disease

Greg Vontz
Chief Executive Officer

435 Tasso Street, Suite 325
Palo Alto, CA 94301
USA

www.topicapharma.com

1 (650) 473-3800

Incorporated: 2008
Ownership: Private

Highlights

Recent

Initiation of Phase II:

A randomized, multi-center, double-blind, placebo-controlled duration- finding study evaluating the efficacy and safety of two-week and four-week once daily treatment of Luliconazole Cream 1% in patients With Tinea Pedis.

Validation of therapeutic efficacy of 5% luliconazole in an in vitro infected toenail model - Complete fungal eradication at 21 days.

Filing of provisional patent for increased solubility, stability and nail penetration with high concentrations of luliconazole.

Upcoming

IND filing for luliconazole in onychomycosis 4Q09.

Completion of phase II trial in tinea pedis 4Q09.

Initiation of phase I trial of luliconazole in onychomycosis 1Q10.

Corporate Mission

Topica's focus is to utilize best in class expertise to license, develop and commercialize genuinely innovative topical prescription products that significantly improve outcomes in patients with serious skin diseases.

Proprietary Technology

Luliconazole ((-)-(E)-[4-(2,4-dichlorophenyl)-1,3-dithiolan-2-ylidene]-1-imidazolylacetonitrile) is a new imidazole antifungal agent.

Corporate Alliances

Nihon Nohyaku Corporation, POLA PHARMA, Prospect Venture Partners.

Products

Name	*Phase*	*Indication*	*Milestone*
Luliconazole	Phase II, IIa, IIb	Tinea Pedis	4Q09
Luliconazole	Phase I	Onychomycosis	4Q09
Luliconazole	Preclinical	Seborrheic Dermatitis	

Senior Management

Greg Vontz, Chief Executive Officer • **Joe Golemme**, Chief Financial Officer • **Nori Nakamura, PhD**, Business Development

Financing History

Round Date (Amount, US$): August 2008 (6.50 Million)

Vivaldi Biosciences, Inc.

Biopharmaceuticals

Douglass Given, MD, PhD, MBA
President & CEO

Bellevue Hospital Center
462 First Avenue, Building A, 9th Floor
New York, NY 10016
USA

www.vivaldibiosciences.com

1 (415) 835-9395

Incorporated:	2008
Employees:	30
Ownership:	Private

Corporate Mission

Vivaldi Biosciences Inc. is developing novel vaccines with the potential for increased effectiveness in the prevention of common seasonal influenza ("flu") and emergent pandemic flu. The company was founded to commercialize patented vaccine and virus technologies developed over the course of a decade by Dr. Peter Palese and Dr. Adolfo García-Sastre at the Mount Sinai School of Medicine.

Vivaldi is developing live attenuated influenza vaccines by altering the gene for nonstructural protein 1 (NS1), a major virulence factor of influenza. Vivaldi scientists are working closely with Elliott Kieff, MD, PhD of Brigham and Women's Hospital, Harvard Medical School, and with Drs. Palese and García-Sastre to select and evaluate candidate vaccines in preparation for an IND application and Phase I clinical study in seasonal flu. Vivaldi is developing standardized cell culture methods using proprietary reverse genetics technologies, and with its cGMP production partner plans to use Vero cell culture for rapid, cost-effective vaccine production and timely distribution.

Vivaldi's proprietary technologies provide an advanced and highly differentiated approach to development and production of vaccines. Vivaldi is undertaking a program to develop a more effective seasonal flu vaccine addressing the unmet needs of adults age 50 and over. Conventional inactivated vaccines for seasonal flu work best in young adults, but are only 30% to 40% protective for illness in the elderly. The over-fifty population is the largest market segment in developed countries and has the greatest need for an improved vaccine for seasonal flu.

Vivaldi also plans to deploy its technologies in the development of vaccines for pandemic flu to meet the urgent demands of an emergent pandemic strain. Vivaldi's altered-NS1 vaccines may provide protection with a single, low-dose immunization via nasal spray, suitable for mass administration in the event of a pandemic.

Senior Management

Douglass Given, MD, PhD, MBA, President & CEO • **David Liebowitz, MD, PhD**, Chief Scientific Officer • **William Wick, MBA**, Chief Financial Officer

Zafgen, Inc.

Biopharmaceuticals

Thomas E. Hughes, PhD
President & CEO

One Broadway, 16th fl
Cambridge, MA 02142
USA

www.zafgen.com

1 (617) 864-1645

Incorporated: 2005
Ownership: Private

Corporate Mission

At Zafgen, we are dedicated to developing novel therapeutics to treat obesity, one of the world's most critical and widespread health issues, affecting an estimated 400 million people globally.

Zafgen is the first biopharmaceutical company dedicated to developing novel obesity therapeutics based on vascular targeting in adipose tissue (fat). Our groundbreaking approach directly targets adipose vasculature to shrink fat cells and help the body sustain a lean, healthy state.

Senior Management

Thomas E. Hughes, PhD, President & CEO • **James E. Vath, PhD**, Other • **Andrew J. Nichols, PhD**, Other